Alkem Laboratories Ltd.

BSE : 212427 NSE : ALKEM ISIN : INE540L01014 Industry : Pharmaceuticals & Drugs
5,044.05
Change: -17.80 (-0.35 %)
As on 27-Feb-2024 12:00 AM
Prev.Close 5,061.85
Open 5,010.00
Day's High 5,096.35
Day's Low 4,934.65
Mkt.Cap ( Cr.) 60,309.18
Face Value 2.00
PE Ratio 38.46
PB Ratio 4.49

52 Week High Low

Low: 3,042.30
High: 5,520.00
LTP:5,044.05

Lifetime High Low

Low: 1,152.50
High: 5,520.00
LTP:5,044.05

Alkem Laboratories Ltd.

BSE : 212427 NSE : ALKEM ISIN : INE540L01014 Industry : Pharmaceuticals & Drugs
5,037.25
B S Sip
Change: -23.05 (-0.46 %)
As on 27-Feb-2024 12:00 AM
Prev.Close 5,060.30
Open 5,029.80
Day High 5,094.60
Day Low 4,946.10
Mkt.Cap ( Cr. ) 60,227.88
Face Value 2.00
P/E Ratio 38.46
PB Ratio 4.49

52 Week High Low

Low:2,835.05
High:5,519.10
LTP:5,037.25

Lifetime High Low

Low:1,175.00
High:5,519.10
LTP:5,037.25

P/E Ratio

52 W L(14.96)
52 W H(40.26)

P/E Ratio

52 W L(14.96)
52 W H(40.26)
Had I Invested a sum of 1,00,000 on the same day 5 years ago,the money would have become 286789.29 ( a of 23.46 p.a.)

Key Levels

Support Level 1 4,675.97
Support Level 2 4,290.08
Resistance Level 1 5,430.77
Resistance Level 2 5,799.68

Moving Average

20 Days 5,205.16
50 Days 5,105.95
100 Days 4,611.61
200 Days 4,107.00
Sotac Pharmaceuticals Ltd. 154.00 Change: 17.00 (12.41%)
PE : 66.22
1Y Return: 0.00%

B S
Dishman Carbogen Amcis Ltd. 254.20 Change: 16.30 (6.85%)
PE : 0.00
1Y Return: 113.97%

B S
SMS Pharmaceuticals Ltd. 153.10 Change: 8.05 (5.55%)
PE : 31.53
1Y Return: 125.98%

B S
Wanbury Ltd. 175.90 Change: 8.35 (4.98%)
PE : 23.52
1Y Return: 349.87%

B S
FY 2023FY 2022FY 2021FY 2020FY 2019
EBDITA Margin (%)17.2721.6428.1322.3918.67
PBT Margin (%)13.9418.8724.7819.1615.83
PAT Margin (%)11.9216.5922.1618.1013.41
ROCE (%)13.1717.9623.4320.4617.05
ROE (%)12.5418.8324.2321.5315.45
FY 2023FY 2022FY 2021FY 2020FY 2019
Total Income ( Cr.)9,320.849,029.707,409.696,773.065,781.67
Gross Profit ( Cr.)1,556.841,972.352,096.011,524.921,085.03
Profit Before Tax ( Cr.)1,326.991,753.371,884.301,338.08943.96
Tax ( Cr.)192.52212.12199.2273.66144.12
Profit After Tax ( Cr.)1,134.471,541.251,685.081,264.42799.84
NAME DESIGNATION
Manish Narang President - Legal, Company Secretary & Compliance Officer
Basudeo N Singh Chairman
Sandeep Singh Managing Director
Mritunjay Kumar Singh Executive Director
Madhurima Singh Executive Director
Sarvesh Singh Executive Director
Srinivas Singh Executive Director
Arun Kumar Purwar Non Executive Independent Director
Narendra Kumar Aneja Non Executive Independent Director
Sangeeta Singh Non Executive Independent Director
Sudha Ravi Non Executive Independent Director
Dheeraj Sharma Non Executive Independent Director
Sujjain Talwar Non Executive Independent Director
Scheme Name AUM% Value(Rs. Cr.) Holding Date
DSP Midcap Fund - Regular Plan - Growth Know More 4.73 782.59 31-Jan-2024
Axis Midcap Fund - Regular Plan - Growth Know More 1.66 406.26 31-Jan-2024
Nippon India Growth Fund - Growth Option Know More 1.62 394.69 31-Jan-2024
ICICI Prudential ELSS Tax Saver Fund - Growth Know More 1.89 237.76 31-Jan-2024
Kotak Emerging Equity Fund - Growth Know More 0.60 235.92 31-Jan-2024
Alkem Laboratories reports Profit after tax of Rs 5042.30 Mln, in the December 2023 quarter
Type: CORPORATE RESULT
Date: 09-Feb-2024 01:17 PM
--
Alkem Laboratories completes sale of unit in US for consideration of $7.96 million
Type: NEWS
Date: 01-Jan-2024 10:41 AM
All rights, title and interest in the land, improvements and personal property with respect to the said Facility are sold to M/s New Mill Capital Holdings LLC
USFDA concludes inspection at Alkem Laboratories’ API manufacturing facility in Maharashtra
Type: NEWS
Date: 02-Dec-2023 03:42 PM
At the end of the inspection, the Company has received Form 483 with three observations
Alkem Laboratories reports Profit after tax of Rs 6465.10 Mln, in the September 2023 quarter
Type: CORPORATE RESULT
Date: 07-Nov-2023 01:50 PM
--
Alkem Laboratories, Biosergen collaborate to develop anti-infective for fungal infections
Type: NEWS
Date: 25-Sep-2023 10:58 AM
Alkem will manage the first clinical patient trial, which is expected to start immediately after the regulatory approval
Alkem Laboratories reports over 2-fold jump in Q1 consolidated net profit
Type: NEWS
Date: 10-Aug-2023 03:51 PM
Total consolidated income of the company increased by 15.44% at Rs 3,033.56 crore for Q1FY24